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Isotretinoin Revisited: Pluripotent 
Effects on Human Sebaceous Gland 
Cells
Christos C. Zouboulis1,2
Nelson et al. confirmed the previously described antiproliferative effect of 
isotretinoin on human sebocytes. They attributed a portion of this decrease to 
cell cycle arrest and detected sebocyte apoptosis, which was not recapitulated 
by alitretinoin or tretinoin. These events were specific to sebocytes, as isotreti-
noin failed to induce apoptosis in keratinocytes. Isotretinoin-induced apoptosis 
was shown to be an RAR-independent mechanism.
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Isotretinoin (13-cis retinoic acid), the 
compound that has revolutionized 
the treatment of severe acne for over 
25 years, is most effective in reducing 
sebaceous gland size by decreasing pro-
liferation of basal sebocytes, in suppress-
ing sebum production up to 90% by 
inhibiting sebaceous lipid synthesis, and 
in prohibiting the progression of sebo-
cyte differentiation in vivo and in vitro 
(Zouboulis and Orfanos, 2000). Despite 
its undeniable efficacy on acne and 
seborrhea, the molecular basis for the 
unique sebostatic activity of this com-
pound is still not clearly understood. 
It may be the superb, tailored effect of 
isotretinoin on acne and its quick release 
for clinical use that have hindered inter-
est in further basic research on it.
Because retinoids exert most of their 
effects by modulating gene expres-
sion after binding to and/or activating 
nuclear retinoid receptors, the strong 
sebostatic activity of isotretinoin is 
particularly surprising, as it exhibits 
low binding affinities for both cel-
lular retinoic acid-binding proteins 
(CRABPs) I and II as well as for nuclear 
retinoid receptors, retinoic acid recep-
tors (RARs), and retinoid X receptors 
(RXRs) (Siegenthaler and Saurat, 1989). 
In contrast, its stereoisomers tretinoin 
(all-trans retinoic acid) specifically 
binds to CRABPs and RAR and ali-
tretinoin (9-cis retinoic acid) to RXR. 
Tsukada et al. (2000) have partially 
elucidated this apparent contradiction 
by showing that isotretinoin undergoes 
significant and selective isomeriza-
tion to tretinoin in cultured sebocytes. 
Intracellular tretinoin acts via RAR to 
exert its antiproliferative effect on these 
cells. Isotretinoin has, therefore, been 
considered as a prodrug (Sitzmann et 
al., 1995; Tsukada et al., 2000), which 
exhibits its activity through isomeriza-
tion to tretinoin (Tsukada et al., 2000) 
or metabolism to 4-oxo-isotretinoin or 
4-hydroxy-isotretinoin (Zouboulis and 
Orfanos, 2000). The 4-oxo metabolites 
of retinoids have been shown to be 
functionally active in human kerati-
nocytes and fibroblasts by their ability 
to induce changes in gene expres-
sion (Baron et al., 2005). Alternatively, 
isotretinoin has been suggested to act 
in a receptor-independent manner by 
influencing cellular signaling pathways 
through direct protein interactions as 
demonstrated with other retinoids or by 
enzyme inhibition (Imam et al., 2001; 
Karlsson et al., 2003).
Several studies have indicated that the 
effects of retinoids on cell proliferation, 
cell cycle, and apoptosis are retinoid -
specific or cell type-specific events. 
Isotretinoin has been found to be superi-
or to other non-aromatic retinoids, such 
as tretinoin and alitretinoin, in reducing 
sebocyte proliferation and suppressing 
sebum production, whereas most aro-
matic retinoids do not reduce sebum 
synthesis (Zouboulis and Orfanos, 2000). 
This superior effect of isotretinoin has 
been attributed to the delayed initiation 
of retinoid inactivation under incubation 
of sebocytes with isotretinoin, a fact that 
leads to high intracellular tretinoin con-
centrations. In contrast, incubation with 
tretinoin leads to rapid enhancement of 
CRABP-II expression, which reduces the 
free intracellular concentration of tretin-
oin through promotion of its metabo-
lism by cytochrome P450 enzymes, and 
to induction of CYP1A1 expression, a 
major xenobiotic metabolizing enzyme, 
in cultured sebocytes (Tsukada et al., 
2000). The antiproliferative activity of 
retinoids on human sebocytes and rat 
preputial sebocyte-like cells in vitro was 
found to be mediated by RAR (Tsukada 
et al., 2000; Kim et al., 2000).
Human sebocytes have been shown 
to be naturally eliminated by apoptosis 
on their way to terminal differentiation 
before their death and holocrine secre-
tion (Wróbel et al., 2003). Terminal 
differentiation and apoptosis are dif-
ferent genetically programmed cell 
events, both followed by cell death as 
an essential feature of eukaryotic cell 
life. Terminal differentiation of human 
sebocytes is associated with lipid syn-
thesis, accumulation of lipid droplets 
in the cytoplasm, and increase of cell 
volume. Apoptotic events occur in par-
allel, as signs of nuclear degeneration 
followed by cell bursting and death. 
Sebocyte apoptosis in vitro can be 
enhanced in association with increased 
rates of terminal differentiation (Wróbel 
et al., 2003). Among other mechanisms, 
apoptosis has also been attributed to 
RXR nuclear receptor ligands through 
reduction of casein kinase 1α (Zhao et 
al., 2004). Although increased levels of 
caspase 3 were noted in SZ95 sebocytes 
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24 hours after treatment with isotretin-
oin and inhibition of cell growth was 
evident at 7 days, other markers failed 
to provide evidence that SZ95 sebo-
cytes were undergoing apoptosis at 
24 hours in a previous report (Wróbel 
et al., 2003). Fenretinide, another non-
aromatic retinoid, induces apoptosis 
by elevating reactive oxygen species 
and increases inactivation of ceramide 
and caspases (Wu et al., 2001). In addi-
tion, a retinoid-related molecule, AGN 
193198, induces apoptosis without acti-
vation of the classical retinoid receptors 
(Balasubramanian et al., 2005).
A marked decrease in wax esters, a 
slight decrease in squalene, and a rela-
tive increase in cholesterol level have 
been detected in skin surface lipids after 
treatment with isotretinoin (Zouboulis 
and Orfanos, 2000). Oral isotretin-
oin was also shown to decrease the 
triglyceride fraction, whereas free ster-
ols and total ceramides were found 
to be increased in comedonal lipids. 
The inhibitory effect of isotretinoin 
on sebaceous lipids has been attrib-
uted to inhibition of terminal sebocyte 
differentiation (Zouboulis et al., 1994) 
and is probably mediated by both RAR 
and RXR (Tsukada et al., 2000; Kim 
et al., 2000). Moreover, isotretinoin has 
been shown to competitively inhibit 
the 3α-hydroxysteroid activity of retinol 
dehydrogenase, leading to decreased 
androgen synthesis in vitro (Karlsson et 
al., 2003).
Like all retinoids, isotretinoin has 
also been shown to exert anti-inflam-
matory activity through an inhibition 
of the migration of polymorphonuclear 
leukocytes into the skin, supporting its 
role in the reduction of inflammation 
that is associated with acne (Wozel 
et al., 1991). Isotretinoin reduced the 
increased expression of pro-matrix 
metalloproteinase  (MMP)-9 and MMP-
13 in the sebum of acne patients and 
inhibited the arachidonic acid-induced 
secretion and mRNA expression of pro-
MMP-2 and pro-MMP-9 in SZ95 sebo-
cytes in vitro, indicating that the influ-
ence of isotretinoin on sebocyte inflam-
matory signaling is likely to be induced 
by MMP (Papakonstantinou et al., 2005). 
The origin of MMP and tissue inhibitors 
of MMP in sebum has been attributed to 
keratinocytes and sebocytes.
Nelson et al. (2006, this issue) 
reexamine the effects of isotretinoin, 
alitretinoin, and tretinoin on cell pro-
liferation, cell cycle proteins, and 
apoptosis of SEB-1 sebocytes and 
keratinocytes and confirm the previous 
reports concerning the dose- and time-
dependent antiproliferative effect of 
isotretinoin on natural and immortal-
ized SZ95 sebocytes (Zouboulis et al., 
1991; Zouboulis et al., 1999; Tsukada 
et al., 2000). A portion of this decrease 
was attributed to an influence on the 
G1/S phase of the cell cycle, as evi-
denced by decreased DNA synthesis, 
increased p21 protein, and decreased 
cyclin D1 protein, and, therefore, to 
cell cycle arrest. Nelson et al. (2006) 
also confirm that no isotretinoin-
induced apoptosis is apparent within 
a 24-hour treatment period (Wróbel 
et al., 2003). By using annexin V–FITC 
staining, TUNEL staining, and cleaved 
caspase 3 protein analysis, Nelson 
et al. (2006) were, however, able to 
detect a marginal induction of apopto-
sis in SEB-1 sebocytes by isotretinoin 
after 48 and 72 hours of treatment. The 
ability of isotretinoin to induce apopto-
sis was not recapitulated by alitretinoin 
or tretinoin. The induction of cell cycle 
arrest and apoptosis by isotretinoin 
was specific to sebocytes, as the com-
pound failed to induce apoptosis in 
HaCaT keratinocytes or normal human 
epidermal keratinocytes. Furthermore, 
the RAR pan-antagonist AGN 193109 
did not inhibit the apoptosis induced 
by isotretinoin; this suggests an RAR-
independent apoptotic mechanism.
The processes described by Nelson 
et al. (2006), such as cell cycle arrest 
and apoptosis of sebocytes, provide an 
explanation for the histological data 
that demonstrated a drastic decrease 
in the size, shape, and lipid content of 
sebaceous glands in human skin under 
isotretinoin treatment (Landthaler et al., 
1980). Taken together, the existing data 
indicate that, in sebocytes, isotretinoin 
causes inhibition of cell proliferation 
after intracellular metabolism to tretin-
oin by an RAR-mediated pathway and 
cell cycle arrest and apoptosis by an 
RAR-independent mechanism, which 
contributes to its sebosuppressive effect 
(Table 1). Induction of cell cycle arrest 
and apoptosis by isotretinoin is likely to 
contribute to the overall effect on sup-
pression of sebum, but isotretinoin also 
inhibits sebaceous lipid synthesis by 
an RAR- and RXR-mediated pathway. 
Finally, the anti-inflammatory effect 
of isotretinoin has been attributed to a 
reduction of MMP in sebum. The abi-
lity of isotretinoin to induce apoptosis 
Table 1. Isotretinoin effectiveness on human sebocytes
Cellular function Effect Cellular mechanism Molecular mechanism
ProliferationA Inhibition Intracellular isomerization 
in tretinoin
RAR-mediated
Proliferation/ApoptosisA Inhibition/Induction Cell cycle arrest Retinoid receptor-
independent
Lipid synthesisA Reduction Inhibition of terminal 
differentiation
RAR- and RXR-mediated





Infl ammation Inhibition Inhibition of the 
migration of neutrophils




 The processes described 
by Nelson et al. provide 
an explanation for the 
histological data that 
demonstrated a drastic 
decrease in the size, 
shape, and lipid content 
of sebaceous glands 
in human skin under 
isotretinoin treatment.
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is specific to sebocytes, not to kerati-
nocytes, and is distinct from effects 
observed with alitretinoin and tretinoin 
that may account, in part, for the supe-
rior efficacy of isotretinoin in reducing 
sebum production.
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Photoadaptation: A Path Toward 
Rational Phototherapy Protocols
Iltefat Hamzavi1
Photoadaptation is defined as the diminished future response to equivalent 
doses of irradiation. It is most often estimated in vivo by looking at changes in 
the minimal erythema dose with subsequent doses of UV radiation. Although 
photoadaptation’s mechanism of action is poorly understood, Palmer et al. 
help clarify the clinical significance of photoadaptation for the dosimetry of 
UV-based phototherapy.
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“Doc, I always burn when I go south. Is 
it okay for me to get a base tan before I 
go on vacation so I don’t burn?” “Why is 
the dose of phototherapy increased with 
each treatment, and how do you know 
how much to increase it?”
Clinicians and educators often hear 
these questions from patients and resi-
dents. These questions show an inher-
ent understanding about the basis of 
the work of Palmer et al. (2006) in the 
June issue of the Journal of Investigative 
Dermatology. This phenomenon is 
known as photoadaptation, tolerance, 
accommodation, or acclimatization. 
“Tolerance” and “photoadaptation” 
are the most common terms, and the 
concept has been defined as the “dimin-
ished future response to equivalent doses 
of irradiation” (Oh et al., 2004). It has 
been reported since the beginning of the 
twentieth century and was thought to be 
due to cutaneous pigmentation, epider-
mal hyperplasia, and hyperkeratosis of 
the stratum corneum (Meischer, 1930). It 
is most often estimated in vivo by look-
ing at changes in the minimal erythema 
dose (MED) with subsequent doses of 
UV radiation. Studies such as the work 
reported by Gonzalez et al. (1996) have 
attempted to evaluate the rate of photo-
adaptation by looking at changes in the 
MED. This is a very tedious and labor-
intensive technique but is the basis of the 
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